Meningioma Diagnosis
Meningioma Diagnosis
Most meningiomas are diagnosed from the scan. Contrast-enhanced MRI shows a tumour arising from the covering of the brain, with a characteristic pattern of enhancement and a clear relationship to the brain, the skull and the large veins — enough, in a typical case, to make a plan without examining tissue. What tissue provides is the grade, and the grade is what decides how closely the tumour is followed and whether radiation belongs in the initial treatment.
Imaging: what MRI shows, and what CT adds
Contrast-enhanced MRI is the investigation that establishes the diagnosis in most cases, and it answers the questions on which the plan depends:
- Where the tumour arises from. A meningioma is attached to the covering of the brain, and this attachment is what distinguishes it from a tumour growing within the brain tissue.
- Its relationship to the structures that matter. Whether it lies against a large vein, against the optic nerve or the nerves for hearing and balance, or against an artery at the base of the skull — the finding that decides how far an operation can safely go.
- Whether it is pressing on the brain or has grown into it. Invasion of the brain next to the tumour is one of the findings that raises the grade, and it can be suspected from the scan and confirmed by the pathologist.
- Whether the flow of fluid is obstructed. A tumour in certain positions can block the circulation of cerebrospinal fluid and cause pressure to rise, which changes how urgently treatment is needed.
- What CT adds. Calcification within the tumour and the thickening of the bone that a minority of meningiomas cause are seen well on CT, and CT is used when MRI cannot be performed.
- What imaging of the veins adds. When the tumour lies against a venous sinus, a study of the veins shows whether that channel is narrowed or blocked, which directly affects the surgical plan.
A repeat scan at an interval is itself a diagnostic step for a small tumour that is causing nothing, because whether it is growing is what determines whether treatment is needed. That is why the earlier images, rather than only the latest report, are worth keeping: the comparison is what carries the information.
When tissue is examined
A meningioma that looks typical and is going to be observed does not need a biopsy. Tissue is examined in specific situations, and each has a purpose:
- When the tumour is removed. This is the usual route, and the tissue establishes the grade with certainty.
- When the appearance is not typical. Some tumours that arise from the covering of the brain are not meningiomas, and some tumours within the brain can resemble them; where the imaging leaves the diagnosis in doubt, tissue settles it.
- Before treatment that depends on the grade. Since atypical and anaplastic tumours are treated with radiation as well as surgery, establishing the grade before the plan is fixed can change what is offered.
- When the tumour recurs. A tumour that has returned may have a higher grade than the original, and retesting it can change the treatment.
- How it is taken — at an operation to remove the tumour, or by a stereotactic biopsy when the tumour lies where removal or a direct approach is not safe.
The grade, and why it decides the follow-up
The grade is the finding that determines how closely the tumour is watched after treatment, and it is established by the pathologist rather than by the scan:
- Grade 1 — the tumour resembles the normal cells of the covering of the brain. Complete removal is the aim, and for a small tumour causing nothing, observation is a legitimate alternative.
- Grade 2, atypical — a higher rate of cell division, or invasion into the brain next to the tumour. Followed more closely, and radiation is considered even when removal appeared complete.
- Grade 3, anaplastic — the rarest and most aggressive group, treated with surgery and radiation together from the outset.
- What raises the grade — a high rate of cell division, invasion of the brain, and certain patterns of cell death within the tumour. Some of these cannot be seen on any scan and are only found by examining the tissue.
- Why the number matters rather than the name — the words used for a tumour's appearance vary between reports, but the grade is what determines the plan; a report that gives the appearance without a grade is incomplete.
The molecular findings, and when they matter
Molecular testing does not define the diagnosis here as it does in some brain tumours, but in selected cases it changes how closely a patient is followed:
- NF2 alteration — found in a substantial share of meningiomas, and central to neurofibromatosis type 2. Where the condition is present, it determines the surveillance programme for the rest of the nervous system.
- CDKN2A/B deletion and TERT promoter mutation — two changes associated with a greater chance of recurrence, which support treating a tumour as higher grade when the appearance alone is not decisive.
- BAP1 loss and SMARCE1 changes — findings that occur in particular variants and occasionally point to an inherited predisposition needing its own follow-up.
- AKT1, SMO, KLF4 and TRAF7 changes — found in a subset of grade 1 tumours, and the subject of research into drug treatment for tumours that recur.
- When testing is worth asking for — in a tumour that is atypical, in one that was not completely removed, and in one that has returned. In a clearly grade 1 tumour removed completely, it rarely changes anything.
How the site shapes the plan
No decision about a meningioma is made without weighing the site, because the structures next to the tumour are what limit both surgery and radiation:
- Over the surface of the brain. Removal is often complete, and the limiting structure is usually the large vein that runs along the midline, which cannot be sacrificed.
- At the base of the skull. The tumour lies against the nerves for sight, smell, hearing and balance, and against the arteries at the base of the brain. Removal is planned to take as much as is safe, and the remainder is treated with precisely aimed radiation.
- Against a venous sinus. The channel that drains blood from the brain may be narrowed by the tumour, and imaging of the veins before any operation is what makes the plan safe.
- Within the ventricles, along the optic nerve, or in the spinal canal. Each position has its own pattern of symptoms and its own balance between the risk of operating and the risk of leaving the tumour alone.
- Where the tumour cannot be reached safely at all, which is a situation in which radiation, rather than surgery, becomes the primary treatment.
What the diagnosis should establish
By the end of the assessment, these are the questions that should have been answered, and asking for them by name is a reasonable check:
- What the tumour is attached to, and where it sits, in terms that name the structures nearby rather than only the lobe of the brain.
- How large it is and whether it has changed compared with any earlier scan — a comparison rather than an absolute measurement.
- What its grade is, or what has to be done to establish it, and what that grade would change.
- Whether it is pressing on the brain, invading it, or obstructing the flow of fluid, each of which affects how urgent treatment is.
- What the options are — observation, surgery, radiation, or a combination — and what would cause the recommendation to change.
- What the follow-up would consist of, with intervals, for whichever option is chosen.
The reason to insist on all six is that a meningioma is often managed over many years, and each of these findings can alter what is done at a later stage. A plan that records them can be reviewed later on the basis of facts; a plan that records only a conclusion cannot.